Abstract
Nowadays, cancer therapy remains limited by the conventional one-size-fits-all approach. In this context, treatment decisions are based on the clinical stage of disease but fail to ascertain the individual ´s underlying biology and its role in driving malignancy. The identification of better therapies for cancer treatment is thus limited by the lack of sufficient data regarding the characterization of specific biochemical signatures associated with each particular cancer patient or group of patients. Metabolomics approaches promise a better understanding of cancer, a disease characterized by significant alterations in bioenergetic metabolism, by identifying changes in the pattern of metabolite expression in addition to changes in the concentration of individual metabolites as well as alterations in biochemical pathways. These approaches hold the potential of identifying novel biomarkers with different clinical applications, including the development of more specific diagnostic methods based on the characterization of metabolic subtypes, the monitoring of currently used cancer therapeutics to evaluate the response and the prognostic outcome with a given therapy, and the evaluation of the mechanisms involved in disease relapse and drug resistance. This review discusses metabolomics applications in different oncological processes underlining the potential of this omics approach to further advance the implementation of precision medicine in the oncology area.
Keywords: Precision medicine, Metabolomics, Oncology, Biomarker, NMR, PLS-DA.
Current Topics in Medicinal Chemistry
Title:Metabolomics Applications in Precision Medicine: An Oncological Perspective
Volume: 17 Issue: 24
Author(s): Leonor Puchades-Carrasco and Antonio Pineda- Lucena*
Affiliation:
- Drug Discovery Unit, Instituto de Investigación Sanitaria La Fe, Valencia,Spain
Keywords: Precision medicine, Metabolomics, Oncology, Biomarker, NMR, PLS-DA.
Abstract: Nowadays, cancer therapy remains limited by the conventional one-size-fits-all approach. In this context, treatment decisions are based on the clinical stage of disease but fail to ascertain the individual ´s underlying biology and its role in driving malignancy. The identification of better therapies for cancer treatment is thus limited by the lack of sufficient data regarding the characterization of specific biochemical signatures associated with each particular cancer patient or group of patients. Metabolomics approaches promise a better understanding of cancer, a disease characterized by significant alterations in bioenergetic metabolism, by identifying changes in the pattern of metabolite expression in addition to changes in the concentration of individual metabolites as well as alterations in biochemical pathways. These approaches hold the potential of identifying novel biomarkers with different clinical applications, including the development of more specific diagnostic methods based on the characterization of metabolic subtypes, the monitoring of currently used cancer therapeutics to evaluate the response and the prognostic outcome with a given therapy, and the evaluation of the mechanisms involved in disease relapse and drug resistance. This review discusses metabolomics applications in different oncological processes underlining the potential of this omics approach to further advance the implementation of precision medicine in the oncology area.
Export Options
About this article
Cite this article as:
Puchades-Carrasco Leonor and Pineda- Lucena Antonio *, Metabolomics Applications in Precision Medicine: An Oncological Perspective, Current Topics in Medicinal Chemistry 2017; 17 (24) . https://dx.doi.org/10.2174/1568026617666170707120034
DOI https://dx.doi.org/10.2174/1568026617666170707120034 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chronic Kidney Disease
The scope of the special thematic issue includes but not limited to the mechanism of chronic kidney disease (CKD), the treatment of renal fibrosis and early diagnosis of CKD and so on. We also welcome manuscripts from other scientific research area with respect to internal medicine. Cell death has been ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Potential of Tetrandrine Against Gliomas
Anti-Cancer Agents in Medicinal Chemistry Alphaviruses and their Derived Vectors as Anti-Tumor Agents
Current Cancer Drug Targets Pro-Oxidant Milieu Blunts Scissors: Insight into Tumor Progression, Drug Resistance, and Novel Druggable Targets
Current Pharmaceutical Design Crocetin, a Carotenoid Derivative, Inhibits VEGF-Induced Angiogenesis via Suppression of p38 Phosphorylation
Current Neurovascular Research Bioactivities of Iridoids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting Role of Glioma Stem Cells for Glioblastoma Multiforme
Current Medicinal Chemistry MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Data Mining of Differentially Expressed Genes in Ovarian Epithelial Carcinoma: Implications in Precise Medicine
Current Topics in Medicinal Chemistry Preparation of Doughnut-like Nanocomposite Colloidal Crystal Particles with Enhanced Light Diffraction Using Drying Self-assembly Method
Current Nanoscience Doxorubicin-Loaded Nanoparticles: New Advances in Breast Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry ADAM Metalloproteinases as Potential Drug Targets
Current Medicinal Chemistry Notch Signalling Pathways and Their Importance in the Treatment of Cancers
Current Drug Targets Biospecies Capture and Detection at Low Concentration
Micro and Nanosystems FER1L4: A Long Non-coding RNA with Multiple Roles in the Occurrence and Development of Tumors
Current Pharmaceutical Design Hexokinase II: The Integration of Energy Metabolism and Control of Apoptosis
Current Medicinal Chemistry Rho GTPase Effector Functions in Tumor Cell Invasion and Metastasis
Current Drug Targets Editorial [Hot Topic: Nongenomic Effects of Thyroid Hormones in Central Nervous System and Skeletal Muscle (Guest Editor: Sandra Incerpi)]
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Editorial [Hot Topic: Novel Peptide-Based Scaffolds for Drug Discovery (Executive Guest Editor: Julio A. Camarero)]
Current Pharmaceutical Design Delivery of Neurotherapeutics Across the Blood Brain Barrier in Stroke
Current Pharmaceutical Design CETUXIMAB: From Bench to Bedside
Current Cancer Drug Targets